Professional Publisher (Small)
|Owner||ecancer Global Foundation (Charity Number 1176307)|
|Address||ecancer Global Foundation
13 King Square Avenue
Bristol BS2 8HU
|Copyright and Licensing||http://ecancer.org/journal/copyright-information.php|
|Copyright and Licensing Policy||Authors will be asked to agree to an exclusive license agreement which states that anyone is free:
If an author believes that an editor has made an error in declining a paper, we welcome an appeal. In your appeal letter to the editor, please state why you think the decision is mistaken. At least two editors decide whether to invite a revised manuscript and whether re-review, or otherwise, is warranted. Authors who have appealed against a rejection but remain concerned about the editorial process can refer their case to COPE. ecancermedicalscience endorses the World Association of Medical Editors (WAME) Policy Statement on Geopolitical Intrusion on Editorial Decisions.
|Publication charge link||http://ecancer.org/journal/charges.php|
|Publication charge policy||We charge authors that have received funding specifically allocated to publication of their articles in an open access journal.|
|OASPA Compliant OA Journals||1|
approx. number in 12 months
|814 articles to date|
|Initiatives||The journal includes a large collection of video interviews with cancer experts at conferences, free accredited education modules for CME and includes Spanish translations for some articles.|
|Peer review policy||http://ecancer.org/ecms/manuscript#publicationManuscripts will be reviewed by one editor and subsequently by one or more experts, with the aim of reaching a first decision as soon as possible, ideally within a month. Statistical reviewers from the European Institute of Oncology and elsewhere may also be used where required.Reviewers are asked whether the manuscript is scientifically sound and how interesting and innovative it is. The ultimate responsibility for any decision lies with the Editor.Reviewers are also asked to indicate which articles they consider to be especially significant for clinical application or public health. These articles may be given greater prominence and included in an editorial and/or ecancermedicalscience press release.
Once an article is accepted, html and pdf versions are published within two weeks on ecancer.org. Authors will be able to check the progress of their paper through the submission system at any time by logging in.